Dispersible tablet
The present invention relates to a tablet comprising Nimorazole. In particular, the invention concerns a pharmaceutical composition or a tablet comprising Nimorazole or a pharmaceutically acceptable salt, for dispersion in water and administration via a tube to a patient with swallowing difficulties.
1. A solid pharmaceutical composition dosage form comprising:
i) nimorazole or a pharmaceutically acceptable salt thereof;
ii) a disintegrant;
iii) a coating sufficient to substantially mask the taste of nimorazole; and
iv) optionally one or more additional excipients;
wherein said solid pharmaceutical composition dosage form allows administration both by directly swallowing the unaltered dosage form and by allowing the dosage form to disintegrate or disperse in an aqueous medium and to be administered to a patient via a feeding tube, and wherein one or more of said dosage forms are dispersible at a concentration of at least 1000 mg nimorazole in 100 ml water at 25° C. within 5 minutes upon stirring, thereby providing a dispersion that passes through a sieve screen with a nominal mesh aperture of 710 μm.
2. The solid pharmaceutical composition dosage form according to claim 1 , wherein the additional excipients comprise a diluent, a binder, a glidant, and a lubricant.
3. The solid pharmaceutical composition dosage form according to claim 1 , further comprising:
an intragranular part, comprising a diluent, a disintegrant, and a binder; and
an extragranular part, comprising a diluent, a disintegrant, a glidant, and a lubricant.
4. The solid pharmaceutical composition dosage form according to claim 1 , wherein said dosage form comprises at least 250 mg of nimorazole or a pharmaceutically acceptable salt thereof.
5. The solid pharmaceutical composition dosage form according to claim 1 , wherein the dosage form is selected from the group consisting of a tablet and a sachet.
6. The solid pharmaceutical composition dosage form according to claim 1 that is formulated as an immediate release tablet or a dispersible tablet.
7. The solid pharmaceutical composition dosage form according to claim 1 , wherein the pharmaceutical composition is manufactured by a process comprising a step of wet granulation, followed by a step of drying until a pre-determined loss on drying (% LOD) is obtained.
8. The solid pharmaceutical composition dosage form according to claim 1 , wherein the pharmaceutical composition is manufactured by a process comprising a step of granulation and optionally a subsequent step of milling, such that essentially all granules are able to pass through a No. 20 sieve.
9. The solid pharmaceutical composition dosage form according to claim 1 , for administration via a feeding tube, wherein the feeding tube is selected from the group consisting of a percutaneous endoscopic gastrostomy tube, a nasogastric feeding tube, a nasojejunal feeding tube, a gastric feeding tube, and a jejunostomy feeding tube.
10. The solid pharmaceutical composition dosage form according to claim 9 , for administration via a percutaneous endoscopic gastrostomy tube or a nasogastric feeding tube.
11. The solid pharmaceutical composition dosage form according to claim 1 , for treatment of cancer by radiosensitizing hypoxic tumor cells.
12. The solid pharmaceutical composition dosage form according to claim 1 , for treatment of patients undergoing irradiation treatment.
13. The solid pharmaceutical composition dosage form according to claim 1 , for treatment combined with chemotherapy.
14. The solid pharmaceutical composition dosage form according to claim 1 , for treatment of an intubated patient.
15. The solid pharmaceutical composition dosage form according to claim 1 , for curative treatment or reirradiation of cancer.
16. The solid pharmaceutical composition dosage form according to claim 1 , for treatment of patients with hypoxic cancer.
17. The solid pharmaceutical composition dosage form according to claim 1 , for treatment of an indication selected from the group consisting of breast cancer, head/neck cancer, lymphoma, cervical cancer, colorectal cancer, brain cancer, lung cancer, bladder cancer, and prostate cancer.
18. The solid pharmaceutical composition dosage form according to claim 17 , for treatment of head/neck cancer.
19. The solid pharmaceutical composition dosage form according to claim 17 , for treatment of cervical cancer or inoperable lung cancer.
20. The solid pharmaceutical composition dosage form according to claim 2 , comprising:
diluent, 1-50 wt %;
disintegrant, 0.5-15 wt %;
binder, 0.5-15 wt %;
glidant, 0.5-3 wt %;
lubricant, 0.5-3 wt %;
optionally one or more additional excipients; and
a coating, 0.5-5 wt %.
21. A kit of parts comprising the solid pharmaceutical composition dosage form according to claim 1 , and instructions for preparing a dispersion of said dosage form for administration via a tube.